Dampening already low expectations for an oral drug against rheumatoid arthritis, AstraZeneca ($AZN) reported today that its midstage study of fostamatinib from partner Rigel failed to show noninferio…
AZ's fostamatinib inferior to Humira in midstage RA trial…
AZ's fostamatinib inferior to Humira in mid-stage RA trial…
LONDON (Reuters) - An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products…
